Experimental pills can be acted as well as the injectable oh jessic style drugs when treating type 2 diabetes.
Orforglipron oral drugs belong to the type of drug called glucagon-similar peptide 1 (GLP-1) action. This class also includes Ozempic, which is made by Novo Nordisk and approved by blood water control aid. Type 2 diabetesNot only treatment for type 2 and those with types, but also Heart disease or Kidney disease. It also has the same active ingredient as Ozempic, but also includes approved Wegovy. Chronic weight management.
The GLP-1 agent is best known as a weight loss drug, and can reduce weight loss by slowing digestion and inhibiting appetite with a mess. Hunger signal. In diabetes, the drug helps to lower blood sugar. Insulin’s boosting levelHormone shining sugar in the blood.
However, GLP-1 is still all-injectable drugs that require refrigerated. The New York Times reported. Introducing a daily pill that can achieve the same results can potentially increase the availability and use of the drug, Lilly, a manufacturer of the drug.
relevant: More than 60 health benefits and the largest ITS study, Ozbig style drugs tied to danger
“Injection cannot be a solution to billions of people around the world.” Dr. Daniel SkovronskyLilly’s chief scientific manager said to New York Times.
~ Inside statement LILLY, published on Thursday (April 17), shared the TOPLINE results of the later exams of Orforglipron. The results of this test have not yet been published in the journal of science, but will be published in the future, and the results will be published in the 85th scientific session of the American Diabetes Association, the statement pointed out.
The test includes 559 adults with type 2 diabetes that are not properly controlled by diet and exercise. Participants have taken orforglipron or placebo every day for more than nine months. Those who take Orforglipron have gained one of three doses of 3 milligrams, 12mg or 36 mg.
After 40 weeks, the test runner uses the blood sugar levels of everyone. A1C testYou can reveal the average blood level level for the previous three months. The test shows the results with a percentage of more than 6.5% diabetes and a percentage of 5.7% to 6.4% signal. Test participants started with an average A1C with 8%.
After 40 weeks, the group that took orforglipron was only 1.3%to 1.6%and placebo for only 0.1%. According to the New York Times, this effect is almost the same as the separate test of Ozempic and Mounjaro, the New York Times reported.
About two -thirds of those with the highest dosage of the drug are the level of 6.5%or less, which is the threshold of diabetes. High -capacity groups also lost 16 pounds (7.3 kilograms) on average. Other medication groups lost about 10 to 12 pounds (4.4 ~ 5.5 kg) and the placebo group lost about 3 pounds (1.3kg).
“At the end of the research, the participants have not yet reached weight, and the complete weight loss seems to have not yet been achieved,” LILLY pointed out.
The most common side effects were moderate in mildness and similar to what could be seen in other GLP-1. For example, diarrhea, nausea, indigestion, constipation and vomiting were more common than placebo in the processing group. The 3%to 8%of the participants in each treatment group decided to stop taking the drug compared to 1%of the placebo.
Lilly will be approved by the Food and Drug Administration later this year, the New York Times reported. In addition to the diabetes test described above, the company tests the drugs of obese adults or tests overweight with at least one weight -related medical problem. It is also used as a treatment for hypertension and sleep apnea for people with obesity.
The price of the pill is not yet announced.
This article is used only for the purpose of providing information and is not intended to provide medical advice.
